Further to the announcement on 2 January 2025 (the “2.4 Announcement”) and the update on the potential combination of Poolbeg and HOOKIPA announced on 7 January 2025, the following amendment
Poolbeg Pharma PLC (AIM:POLB) Update Potential Combination of Poolbeg & HOOKIPA
Further to the announcement on 2 January 2025 (the “2.4 Announcement”), the Boards of Poolbeg and HOOKIPA are pleased to confirm that significant HOOKIPA shareholder, Gilead Sciences Inc. (“Gilead”), has
Poolbeg Pharma PLC (AIM:POLB) Combination of Poolbeg and HOOKIPA Pharma Inc.
The boards of directors (each a “Board”) of HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc (“Poolbeg”) are pleased to announce that they have entered into non-binding discussions for an
Poolbeg Pharma PLC (AIM:POLB) Presents POLB 001 data at 66th ASH Meeting
Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
Poolbeg Pharma PLC (AIM:POLB) POLB 001 Patent Granted in United States
Further strengthens Poolbeg’s robust intellectual property portfolio.
Poolbeg Pharma PLC (AIM:POLB) POLB 001 data to be presented at ASH
Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
Broker reports that Poolbeg Pharma is quickly establishing itself as a specialist in rare diseases.
According to broker Shore Capital, Poolbeg Pharma PLC (AIM: POLB) is making significant progress toward becoming a rare disease company.
Poolbeg Pharma plc (AIM:POLB) Interim results for the six months to 30 June 2024
Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded
Poolbeg Pharma (AIM:POLB) to Present at the H.C. Wainwright 26th Annual Global Investment Conference
27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that
Poolbeg Pharma PLC – Voluntary Delisting from OTCQB Market
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is
Poolbeg Pharma PLC – Chief Executive Officer Jeremy Skillington PhD Talking To Zak Mir
Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD present an overview of their current programmes and opportunities, focussing on POLB 001, data, exclusive option agreement and their AI-powered research using
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
9 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, confirms that the